Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to
Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double
blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the
Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation
induction by CC. Half of them will receive MYO + folic acid (FA) in addition to the CC, while
the other half will receive a placebo containing only FA in addition to the CC. The MYO
supplementation will be initiated at least one month before taking CC and will be continued
throughout this treatment until pregnancy or before switching to another type of treatment
for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Lille
Collaborators:
Laboratoires Besins International Ministry of Health, France